XML 67 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Long-Term Debt (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2019
Nov. 30, 2018
Nov. 30, 2016
Sep. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Long-Term Debt              
Total long-term debt         $ 455,041,000 $ 454,353,000  
Long-term debt interest expense              
Stated coupon interest         28,811,000 9,316,000 $ 7,475,000
Amortization of debt issuance costs         3,051,000 1,166,000 1,072,000
Total long-term debt interest expense         31,862,000 10,482,000 $ 8,547,000
9.0% non-recourse notes due 2033              
Long-Term Debt              
Principal amount         235,347,000 237,500,000  
Unamortized debt issuance costs         $ (6,196,000) $ (7,965,000)  
Long-term debt interest expense              
Proceeds from issuance of debt   $ 250,000,000.0          
Interest rate (as a percent)   9.00%     9.00% 9.00%  
Notes net principal amount         $ 235,300,000    
Percentage of equity interest   63.75%          
9.0% non-recourse notes due 2033 | Level 2              
Long-term debt interest expense              
Notes fair value         228,300,000 $ 237,500,000  
3.25% Convertible Senior Notes Due 2023              
Long-Term Debt              
Principal amount         230,000,000 230,000,000  
Unamortized debt issuance costs         $ (4,110,000) $ (5,182,000)  
Long-term debt interest expense              
Proceeds from issuance of debt     $ 222,500,000        
Interest rate (as a percent)     3.25%   3.25% 3.25%  
Transaction costs     $ 7,500,000        
Conversion rate, in shares         29.0276    
Principal amount for conversion rate         $ 1,000    
Conversion price (in dollars per share)         $ 34.45    
Redemption price to principal amount, in percent         100.00%    
3.25% Convertible Senior Notes Due 2023 | Level 2              
Long-term debt interest expense              
Notes fair value         $ 236,000,000.0 $ 235,000,000.0  
Arbitration against Innoviva and TRC              
Long-term debt interest expense              
Amount of distribution withheld       $ 6,900,000      
TRC              
Long-term debt interest expense              
Percentage of equity interest         85.00%    
TRC | Arbitration against Innoviva and TRC              
Long-term debt interest expense              
Amount of distribution withheld $ 8,000,000.0     $ 8,000,000.0      
Theravance Biopharma R&D, Inc. | 9.0% non-recourse notes due 2033              
Long-term debt interest expense              
Interest rate (as a percent)   5.00%          
Percentage of note to be retained   5.00%